CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 85.4% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Close

Trade Vir Biotechnology VIR

Sell
 Buy

VirBiotechnology live chart

5m 15m 30m 1h 4h 1d 1w

Instrument Fundamentals

Weekly Search
Weekly
Daily
Date Close Change Change (%) Open High Low

News

Webhose 2026 May 09, 05:35

Vir Biotechnology (NASDAQ:VIR) Downgraded to "Sell" Rating by Wall Street Zen

Vir Biotechnology Inc
Webhose 2026 May 07, 09:14

Vir Biotechnology (NASDAQ:VIR) Releases Quarterly Earnings Results, Misses Expectations By $0.84 EPS - Stock Observer

Vir Biotechnology Inc
Webhose 2026 May 07, 08:18

Vir Biotechnology Q1 Earnings Call Highlights

Vir Biotechnology Inc
Webhose 2026 May 07, 05:44

Insider Selling: Vir Biotechnology (NASDAQ:VIR) Director Sells $221,100.00 in Stock - Stock Observer

Vir Biotechnology Inc
Webhose 2026 May 06, 02:04

Vicki Sato Sells 22,000 Shares of Vir Biotechnology (NASDAQ:VIR) Stock - Daily Political

Vir Biotechnology Inc
Webhose 2026 May 05, 06:19

How Insider Sale and VIR-5500 Milestone at Vir Biotechnology (VIR) Have Changed Its Investment Story

Vir Biotechnology Inc
Webhose 2026 May 04, 18:52

Vir Biotechnology (NASDAQ:VIR) Director Vicki Sato Sells 22,000 Shares

Vir Biotechnology Inc
Webhose 2026 May 04, 12:04

Vir Biotechnology (VIR) Projected to Post Quarterly Earnings on Wednesday - Zolmax

Vir Biotechnology Inc
Webhose 2026 Apr 29, 11:49

Vir Biotechnology (VIR) Expected to Announce Quarterly Earnings on Wednesday

Vir Biotechnology Inc
Webhose 2026 Apr 28, 03:16

Assessing Vir Biotechnology (VIR) Valuation After Recent Share Price Momentum

Vir Biotechnology Inc
Webhose 2026 Apr 26, 19:43

Is Vir Biotechnology, Inc. (VIR) A Good Stock To Buy Now?

Vir Biotechnology Inc
Webhose 2026 Apr 22, 14:27

Vir Biotechnology (VIR) Posts 80.98% Year-To-Date Growth

Vir Biotechnology Inc
Webhose 2026 Apr 21, 18:19

10 Best Small-Cap Biotech Stocks According to Hedge Funds

Vir Biotechnology Inc
Webhose 2026 Apr 21, 13:09

Vir Biotechnology (VIR) Is Up 19.1% After Astellas Cancer Pact Closes With $315M Inflows

Vir Biotechnology Inc
Webhose 2026 Apr 20, 14:47

Can Vir Biotechnology (VIR)'s Masked T-Cell Technology Crack the Hardest-to-Treat Prostate Cancer?

Vir Biotechnology Inc
Webhose 2026 Apr 20, 13:58

Vir Biotechnology (NASDAQ:VIR) Sets New 1-Year High - Here's Why - Stock Observer

Vir Biotechnology Inc
Webhose 2026 Apr 20, 00:11

Is Vir Biotechnology (VIR) One of the Best Low Priced Biotech Stocks to Invest In?

Vir Biotechnology Inc
Webhose 2026 Apr 16, 22:15

Vir Biotechnology (VIR) Valuation After Astellas Partnership And New VIR 5500 Trial Milestone

Vir Biotechnology Inc
Webhose 2026 Apr 16, 12:05

Vir Biotechnology Announces Closing of Global Strategic Collaboration with Astellas for the Treatment of Prostate Cancer | Morningstar

Vir Biotechnology Inc
Webhose 2026 Apr 13, 14:05

Phase 1 trial designed to assess the safety, pharmacokinetic

Vir Biotechnology Inc
Webhose 2026 Apr 13, 07:45

Brokerages Set Vir Biotechnology, Inc. (NASDAQ:VIR) PT at $20.44

Vir Biotechnology Inc
Webhose 2026 Apr 12, 09:21

Should Vir's CMO Exit and Astellas Funding Boost Reshape How Investors View Its R&D Strategy (VIR)?

Vir Biotechnology Inc
Webhose 2026 Apr 10, 13:51

Vir Biotechnology (VIR) Leading with Its BiTEs Therapy

Vir Biotechnology Inc

VirBiotechnology news

Latest news

Info

Spread

0.07

Spread (%)

0.7701 %

Leverage

1:5

Overnight Interest Buy

-0.0597 %

Overnight Interest Sell

-0.0292 %

Currency

USD

Trading Hours

Markets closed

Monday

13:31 - 19:59

Tuesday

13:31-19:59

Wednesday

13:31-19:59

Thursday

13:31-19:59

Friday

13:31-19:59

Analysis and statistics

Open

---

Previous Close

---

52 Week High/Low

--- – ---

Market cap

1538105984

Shares Outstanding

168651974

Earnings Date (Next)

0000-00-00

Div Yield

Ex-Dividend Date

Forward annual dividend rate

0

Forward annual dividend yield

0

EPS

-3.13

Learn more about this instrument

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors. It has grant collaboration and license agreement with Astellas; license agreement with Norgine for the treatment of CHD; amended and restated letter agreement with the Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreement with the Institute for Research in Biomedicine; a license agreement with The Rockefeller University; license agreements with Xencor; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

Related Instruments

Asset
Sell
Buy
Change (%)

Trade Now

Trade Now

Trade Now

Trade Now

Latest Education Articles

Trustpilot